Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Jad Othman

Jad Othman

MBBS

Guy's and St Thomas' NHS Foundation Trust

Outcomes with low-intensity venetoclax in NPM1-mutated AML depend on co-mutational profile

Jad Othman • 10 Dec 2025

The prognostic impact of KMT2A fusion transcript detection in patients with KMT2A-r AML in CR1

The prognostic impact of KMT2A fusion transcript detection in patients with KMT2A-r AML in CR1

Jad Othman • 10 Dec 2025

Prognostic significance of molecular MRD in NPM1-mutated AML treated with venetoclax-based therapy

Prognostic significance of molecular MRD in NPM1-mutated AML treated with venetoclax-based therapy

Jad Othman • 13 Dec 2023

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3-mutated AML

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3-mutated AML

Jad Othman • 13 Dec 2023

The treatment of AML within the United Kingdom NHS framework

The treatment of AML within the United Kingdom NHS framework

Jad Othman • 13 Dec 2023

MRD negativity in NPM1-mutated AML: the influence of co-occurring mutations and FLAG-Ida induction

MRD negativity in NPM1-mutated AML: the influence of co-occurring mutations and FLAG-Ida induction

Jad Othman • 13 Dec 2023

MRD status predicts alloSCT outcomes in NPM1-mutated AML: an analysis of AML17 and AML19 studies

MRD status predicts alloSCT outcomes in NPM1-mutated AML: an analysis of AML17 and AML19 studies

Jad Othman • 12 Dec 2023